Seres Therapeutics

Seres Therapeutics Inc. is a commercial-stage biotechnology company headquartered in Cambridge, Massachusetts, founded by Flagship Pioneering and publicly traded on the Nasdaq under the ticker MCRB. The company is a leading microbiome therapeutics platform company developing a novel class of biological drugs, referred to as live biotherapeutics or... Ecobiotic drugs, that are designed to treat disease by restoring the function of a dysbiotic microbiome where the state of bacterial diversity and function is imbalanced. Seres has a strong development pipeline and rigorous scientific underpinning, working to revolutionize treatment of a wide range of serious diseases by modulating the function of the human microbiome. The company's proprietary discovery and design platform enables it to identify key alterations in the microbiome that are associated with or lead to specific diseases and to rationally design tailored therapies that disrupt the disease state and establish a healthy microbiome. The platform draws on insights into microbial ecology, host immune function, and gut barrier integrity to create oral treatments that act via multiple biological pathways. Seres focuses on implementing its microbiome therapeutics platform to develop live biotherapeutics that treat dysbiosis in the colonic microbiome, with programs targeting infection protection in medically compromised patients and treatments for inflammatory and immune-related gastrointestinal disorders. The company translates microbiome research into clinical development, manufacture, and commercialization of these novel live biotherapeutic medicines. Seres is commercializing its lead approved product in collaboration with Nestle Health Science and continues to advance its pipeline of investigational therapies for serious conditions affecting vulnerable patient populations.Read More